Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells.

Mesenchymal stromal cells (MSCs) have important immunosuppressive properties, but the mechanisms and soluble factors involved in these effects remain unclear. We have studied prostaglandin-E2 (PGE2) as a possible candidate implied in adipose tissue-derived MSCs (Ad-MSCs) immunosuppressive properties over dendritic cells and T lymphocytes, compared to bone marrow derived MSCs (BM-MSCs). We found that both MSCs inhibited the maturation of myeloid-DCs and plasmocytoid-DCs. High levels of PGE2 were detected in DCs/MSCs co-cultures. Its blockade with indomethacin (IDM) allowed plasmocytoid-DCs but not myeloid-DCs maturation. Additionally, high levels of PGE2 were found in co-cultures in which Ad-MSCs or BM-MSCs inhibited activated T cells proliferation and pro-inflammatory cytokines production. PGE2 blockade by IDM preserved T lymphocytes proliferation but did not restore the pro-inflammatory cytokines secretion. However, an increased expression of transcription factors and cytokines genes involved in the Th1/Th2 differentiation pathway was detected in the T cells co-cultured with Ad-MSCs, but not with BM-MSCs. In conclusion, we propose that PGE2 is a soluble factor mediating most of the immunosuppressive effects of Ad-MSCs and BM-MSCs over p-DCs maturation and activated T lymphocytes proliferation and cytokine secretion.

[1]  Min Zhu,et al.  Human adipose tissue is a source of multipotent stem cells. , 2002, Molecular biology of the cell.

[2]  Y. Bae,et al.  Characterization and Expression Analysis of Mesenchymal Stem Cells from Human Bone Marrow and Adipose Tissue , 2004, Cellular Physiology and Biochemistry.

[3]  B. Blazar,et al.  Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.

[4]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[5]  L. Moretta,et al.  MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. , 2009, Blood.

[6]  H. Harizi,et al.  Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  L. Moretta,et al.  Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. , 2006, Blood.

[8]  G. Mancardi,et al.  Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State , 2007, Stem cells.

[9]  J. Moreau,et al.  FunctionsIL-10, Which Down-Regulates Dendritic Cell Enhances the Production of Endogenous 2 Cyclooxygenase-2-Issued Prostaglandin E , 2002 .

[10]  E. Lam,et al.  Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. , 2005, Blood.

[11]  A. Uccelli,et al.  Immunoregulatory function of mesenchymal stem cells , 2006, European journal of immunology.

[12]  P. Hockberger,et al.  PGE2 suppresses mitogen-induced Ca2+ mobilization in T cells. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  R. Willemze,et al.  Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells1 , 2006, The Journal of Immunology.

[14]  J. Banchereau,et al.  IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.

[15]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[16]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[17]  K. Akashi,et al.  Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. , 2009, Blood.

[18]  Q. Han,et al.  Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. , 2007, Transplantation proceedings.

[19]  S. Perez,et al.  Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells , 2006, Stem cells.

[20]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[21]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[22]  Q Han,et al.  Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells , 2006, Bone Marrow Transplantation.

[23]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[24]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[25]  Friedenstein Aj,et al.  Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. , 1982 .

[26]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[27]  D. Jacobsohn,et al.  Acute graft-versus-host disease. , 1990, Cancer treatment and research.

[28]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[29]  M. Choudhry,et al.  PGE(2)-mediated inhibition of T cell p59(fyn) is independent of cAMP. , 1999, The American journal of physiology.

[30]  J. Gimble,et al.  Yield of human adipose-derived adult stem cells from liposuction aspirates. , 2004, Cytotherapy.

[31]  E. Lam,et al.  Mesenchymal Stem Cells Inhibit Dendritic Cell Differentiation and Function by Preventing Entry Into the Cell Cycle , 2007, Transplantation.

[32]  L. Pénicaud,et al.  Immunomodulatory effect of human adipose tissue‐derived adult stem cells: comparison with bone marrow mesenchymal stem cells , 2005, British journal of haematology.

[33]  F. Benvenuto,et al.  Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.

[34]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[35]  Wei Zhang,et al.  Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. , 2004, Stem cells and development.

[36]  O. Ringdén,et al.  Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. , 2005, Experimental cell research.

[37]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[38]  J. Blay,et al.  Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.

[39]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[40]  F. Djouad,et al.  Mesenchymal Stem Cells Inhibit the Differentiation of Dendritic Cells Through an Interleukin‐6‐Dependent Mechanism , 2007, Stem cells.

[41]  W. Ansorge,et al.  Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. , 2005, Experimental hematology.

[42]  M. Sykes,et al.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. , 2007, Blood.

[43]  F. Guilak,et al.  Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. , 2003, Cytotherapy.

[44]  F. Benvenuto,et al.  Reciprocal Interactions Between Human Mesenchymal Stem Cells and γδ T Cells Or Invariant Natural Killer T Cells , 2009, Stem cells.

[45]  F. Marini,et al.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. , 2005, Cytotherapy.

[46]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[47]  H. Koo,et al.  Gene expression profile of cytokine and growth factor during differentiation of bone marrow-derived mesenchymal stem cell. , 2005, Cytokine.

[48]  V. Levitsky,et al.  Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes , 2007, Journal of leukocyte biology.

[49]  R. Yañez,et al.  Adipose Tissue‐Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graft‐Versus‐Host Disease , 2006, Stem cells.

[50]  Yi Zhang,et al.  Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. , 2005, Blood.

[51]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.